What Is Apixaban (Eliquis)? Why Is It Used in Cancer?
In this article
Apixaban (original brand name Eliquis) is an oral anticoagulant that selectively and reversibly inhibits factor Xa, which is involved in clot formation. It reduces the blood's tendency to clot and helps prevent new clots. It belongs to the "direct oral anticoagulant," or "DOAC," class.
Apixaban is approved for several conditions, including reducing stroke risk, treating clots in deep veins (deep vein thrombosis, DVT) and clots traveling to the lungs (pulmonary embolism, PE), and preventing their recurrence.
It is also now one of the most frequently preferred medicines for treating cancer-associated venous thromboembolism—clots in leg veins or pulmonary vessels related to cancer—and is included in major oncology guidelines.
How does it work?
Apixaban blocks factor Xa , an enzyme with a central role in the coagulation cascade. Factor Xa is essential for converting prothrombin to thrombin and ultimately forming a fibrin clot. By interrupting this chain, apixaban suppresses new clot formation and limits the growth of an existing clot.
This mechanism provides "systemic anticoagulation," but unlike the traditional anticoagulant warfarin, it does not require frequent INR monitoring and is taken orally at fixed doses. This is particularly convenient for cancer patients who cannot attend hospital frequently or have vascular-access problems.
For which conditions is apixaban officially indicated (FDA, etc.)?
According to the current product information, apixaban is indicated for the following conditions in adults:
- Nonvalvular atrial fibrillation (an irregular heart rhythm): To reduce the risk of a clot traveling to the brain (stroke) and systemic embolism.
- Clot prevention after hip or knee replacement: To prevent deep vein thrombosis (DVT) after major orthopedic surgery and subsequent pulmonary embolism (PE).
- Treatment of DVT and PE: To treat clots in leg veins and/or pulmonary embolism.
- Prevention of recurrent DVT/PE: Long-term low-dose maintenance treatment to reduce recurrence risk after initial treatment.
- Pediatric VTE: Treatment of venous thromboembolism and prevention of recurrence in children, including newborns, after at least 5 days of initial anticoagulant treatment.
What is apixaban's role in cancer patients?
Cancer cells release substances that trigger clotting; chemotherapy, central venous catheters, immobility, and surgery further increase this risk. Consequently, venous thromboembolism—leg-vein clots (DVT) or pulmonary embolism (PE)—is common and potentially fatal in cancer patients. This is called cancer-associated thrombosis / cancer-associated venous thromboembolism (cancer-associated VTE) .
The previous standard was long-term low-molecular-weight heparin injections, such as enoxaparin. Current international guidelines (ASCO, NCCN, ASH, etc.) state that, for most cancer patients, apixaban or other DOACs (rivaroxaban, edoxaban) may be among the first choices. Apixaban is at least as effective as heparin, and some trials have found an acceptable risk of major bleeding.
Long-term treatment: Clot recurrence risk persists while cancer remains present. Apixaban can therefore be used for months, or longer while cancer remains active. Guidelines support extending treatment beyond month 6 if bleeding risk is not high.
Low-dose maintenance: Recent studies found that, beyond 6 months, apixaban 2.5 mg twice daily (a lower dose than the standard 5 mg x2) effectively prevents recurrent clots in cancer patients and can reduce bleeding risk. This is an important strategy for active-cancer patients who need long-term anticoagulation but are concerned about bleeding.
Dosing and Administration Schedule (Adults)
| Indication | Recommended starting dose | Maintenance / Long term | Typical treatment duration |
|---|---|---|---|
| Nonvalvular atrial fibrillation | 5 mg orally, 2 times daily | May be reduced to 2.5 mg x2 if at least 2 criteria are met: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL | Long term; chronic use according to stroke risk |
| Acute DVT / PE treatment | Usually 10 mg 2 times daily for the first 7 days (the conventional product-information regimen), followed by 5 mg 2 times daily | 5 mg 2 times daily in the stable phase | At least 3-6 months, extended according to clinical judgment |
| Prevention of recurrent DVT / PE (extended treatment) | After the acute phase | 2.5 mg 2 times daily | Long term while recurrence risk persists |
| Clot prevention after hip / knee replacement | 2.5 mg 2 times daily | - | ~35 days after hip surgery, ~12 days after knee surgery |
| Cancer-associated venous thrombosis (CAT) | Usually starts according to the DVT/PE treatment protocol (high dose → 5 mg x2) | After month 6, if bleeding risk permits, 2.5 mg x2 low-dose maintenance may be considered (extended treatment) | While cancer remains active, as long as bleeding risk is tolerable |
Route of administration: Taken orally as a tablet, with or without food, at regular intervals (usually every 12 hours).
Monitoring: Routine INR monitoring is unnecessary, but kidney function, liver function, and blood counts—particularly hemoglobin/hematocrit and platelets—should be checked periodically. Ask about signs of overt or occult bleeding at every visit.
Absorption, Distribution, Metabolism, Elimination (Pharmacokinetics)
| Parameter | Explanation |
|---|---|
| Absorption | Apixaban is well absorbed orally; bioavailability is high, and fixed doses generally produce predictable blood concentrations. Food does not substantially impair bioavailability. |
| Distribution | It is highly bound to plasma proteins. This explains why even small changes in free drug can produce effective anticoagulant activity. |
| Metabolism | Partly metabolized in the liver by cytochrome P450 enzymes, particularly CYP3A4; it is also eliminated through the gut. Interactions with strong CYP3A4 and P-gp inhibitors or inducers are therefore possible. |
| Elimination | Apixaban is cleared through both the kidneys and liver. It is not exclusively renally eliminated, so it may be preferred to alternatives such as rivaroxaban in some patients with kidney impairment; advanced kidney or liver impairment nevertheless requires caution. |
Which Patients Are Suitable Candidates?
- Suitable candidates: Patients with cancer-related or non-cancer-related venous thrombosis, no active major bleeding, acceptable kidney and liver function, and the ability to take oral medicines regularly.
- Patients with nonvalvular atrial fibrillation: Adults with high stroke risk and an acceptable bleeding risk.
- Patients undergoing major orthopedic surgery: Patients requiring DVT/PE prophylaxis after hip or knee replacement.
Precautions / Relative Contraindications:
- Active, uncontrolled major bleeding
- Recent major surgery or an unhealed wound
- Severe thrombocytopenia, particularly very low platelets caused by chemotherapy; bleeding risk may be extremely high.
- Advanced liver impairment with a bleeding tendency
- Spinal/epidural catheters or recent spinal procedures (risk of spinal/epidural hematoma)
- In patients with active brain metastases or primary brain tumors, assess bleeding risk individually and exercise greater caution in most cases.
Apixaban Drug Interactions
Apixaban is metabolized and transported through intestinal and hepatic CYP3A4 and P-glycoprotein (P-gp) pathways. Medicines strongly inhibiting or inducing these pathways can therefore change apixaban blood concentrations.
- Strong CYP3A4 / P-gp inhibitors (such as certain azole antifungals and macrolide antibiotics) can raise apixaban levels → increased bleeding risk. In oncology, this is particularly important in patients with bone marrow suppression receiving antifungal prophylaxis/treatment.
- Strong CYP3A4 / P-gp inducers (such as certain antiepileptics) can lower apixaban levels and reduce efficacy → increased risk of recurrent clots.
- Other anticoagulants / antiplatelet agents (heparin, enoxaparin, clopidogrel, aspirin, NSAIDs, etc.): combined use synergistically increases bleeding risk. These combinations require a strong clinical rationale and close monitoring.
Adverse Effects
Common / Expected Effects
- Bleeding: Nosebleeds, gum bleeding, and easy bruising can occur frequently. These are usually mild.
- Dizziness, weakness (hemoglobin may fall, particularly with occult bleeding)
- Indigestion, mild stomach symptoms
Serious but Less Frequent Effects
- Major bleeding: Gastrointestinal bleeding, blood in urine, coffee-ground-like bloody vomit, black stools (melena), and signs of brain hemorrhage such as sudden severe headache, visual/speech disturbance, or confusion
- Spinal / epidural hematoma: Particularly associated with procedures such as spinal anesthesia, epidural catheters, or lumbar puncture. This can compress nerves and cause permanent paralysis; apixaban must therefore be interrupted/bridged under medical supervision when such procedures are planned.
Pretreatment Checks and Monitoring During Treatment
- Blood count: Hemoglobin (occult bleeding?), platelets (bleeding risk?)
- Kidney function (creatinine): Dosing decisions are individualized in advanced kidney impairment.
- Liver function: Severe liver impairment can increase the tendency to bleed.
- Concomitant medicines: Review bleeding risk with antifungals, antibiotics, and targeted antiangiogenic medicines such as bevacizumab that affect vessel structure.
- Surgical plans: If biopsy, port placement, tissue removal by biopsy, major surgery, or similar procedures are planned, determine beforehand when to stop apixaban.
Dose Modifications and Temporary Treatment Interruption
- If major bleeding develops: Apixaban may be stopped urgently and the patient directed to emergency care. Specific antidotes—factor Xa inhibitor reversal agents—are available at some centers; this decision is made at hospital level.
- Before an invasive procedure / surgery: Apixaban is generally stopped 24–48+ hours beforehand, depending on procedure-related bleeding risk and kidney function. A physician must determine the timing; patients should not stop or restart it themselves.
- Long-term maintenance: After the acute phase, such as after month 6 in cancer-associated DVT/PE treatment, the dose can generally be reduced to 2.5 mg 2 times daily to balance efficacy against bleeding risk. This is an individual patient decision.
SGK Reimbursement and Licensing in Türkiye
Apixaban in Türkiye (Eliquis or equivalent products)has long been licensed as an anticoagulant and is widely prescribed in cardiology for stroke prevention in nonvalvular atrial fibrillation, orthopedics for clot prophylaxis after hip/knee replacement, and vascular surgery, respiratory medicine, internal medicine, and oncology for DVT/PE treatment and recurrence prevention.
SGK (Social Security Institution) reimbursement
requires documentation in a medical board report for patients with nonvalvular atrial fibrillation without moderate-to-severe mitral stenosis or a mechanical prosthetic valve, who have one or more of: a history of stroke or transient ischemic attack, age ≥75, heart failure of NYHA Class ≥II, diabetes mellitus, or hypertension;
after at least 2 months of warfarin, if the target INR of 2-3 cannot be maintained in at least three of the last 5 measurements taken at least one week apart, warfarin may be stopped and treatment switched to dabigatran, rivaroxaban, apixaban, or edoxaban.
Patients who have a cerebrovascular event while taking warfarin may switch directly to dabigatran, rivaroxaban, apixaban, or edoxaban.
Rivaroxaban, dabigatran, edoxaban, and apixaban are used to treat deep vein thrombosis (DVT) and prevent recurrent DVT and pulmonary embolism (PE) after acute DVT, or to treat PE and prevent recurrent PE and DVT.
Previous warfarin use is not required in patients with recurrent idiopathic pulmonary embolism, homozygous thrombophilia, active cancer with a previous venous thromboembolism (VTE), or immobility with the reason documented in the report.
13. Precautions When Taking Apixaban (For Patients)
- Do not skip doses. Apixaban's effect declines quickly; missed doses increase clot risk.
- Do not take a double dose. Do not take two tablets together to make up for a missed dose; this increases bleeding risk.
- Tell your physician if a new medicine is added. This includes antibiotics, antifungals, herbal supplements, and painkillers, particularly NSAIDs such as ibuprofen and naproxen.
- Even minor procedures such as tooth extraction, endoscopy, biopsy, or port placement matter. Tell the team you take apixaban before such procedures are planned; a plan to interrupt it several days beforehand may be necessary.
- Uncontrolled bruising, nosebleeds, dark stools, blood in urine, dizziness, headache, or visual/speech disturbance are emergency warning signs. Call your healthcare team immediately or go to emergency care.
- For patients with active cancer: Severe vomiting/diarrhea on chemotherapy days can affect apixaban absorption. Call your oncology team rather than adjusting it yourself.
14. References
- Eliquis® (apixaban) Full Prescribing Information, US FDA labeling document, revised April 2025. Indications: reducing stroke and systemic embolism risk in nonvalvular atrial fibrillation; DVT prophylaxis after hip/knee replacement; DVT and PE treatment; reducing DVT/PE recurrence risk; pediatric VTE treatment. Dosing schedules and spinal/epidural hematoma warnings are defined here.
- StatPearls, Apixaban (NCBI Bookshelf, updated 2024). Apixaban's factor Xa inhibitor mechanism, pharmacokinetics (oral bioavailability, CYP3A4/P-gp metabolism, hepatic/renal elimination), and principles of anticoagulant use.
- ASCO Venöz Tromboembolizm (VTE) Profilaksisi ve Tedavisi Kılavuz Güncellemesi (Journal of Clinical Oncology; kanser cerrahisi sonrası ve aktif kanserli hastada tedavi kısmı, apiksaban ve rivaroksabanın eklenmesi). This update strongly recommends apixaban for cancer-associated thrombosis treatment and prophylaxis in selected high-risk oncology patients.
- NCCN, ASH, and international cancer thrombosis guidelines (2023–2024 versions): DOACs (apixaban, rivaroxaban, edoxaban) and/or low-molecular-weight heparin are recommended as first choices for cancer-associated VTE; individualized selection is emphasized in GI tumors because of bleeding risk, with caution in active brain metastases or severe thrombocytopenia.
- API-CAT / long-term low-dose apixaban studies (NEJM and major conference presentations, 2025): In active-cancer patients receiving anticoagulation for more than 6 months, low-dose apixaban 2.5 mg 2 times daily showed similar efficacy in preventing recurrent clots to the full dose of 5 mg 2 times daily, with a trend toward fewer bleeding events. This is one of the new standards for long-term maintenance in cancer patients.
- SGK / SUT updates and Turkish Pharmacists' Association announcements (2025): Reimbursement of new-generation oral anticoagulants, including apixaban, requires a specialist physician's report and specified indications; reimbursement is possible in defined clinical scenarios, and similar report-based reimbursement models apply to cancer medicines.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.